Abstract: A device (20) for creating cell-exclusion zones comprises a baseplate (21) having a first major face from which a plurality of exclusion reliefs (22) project, each exclusion relief (22) having at least one distal end (23) configured for contact with a bottom (11b) of a respective well (11) of a multi-well cell-culture plate (10). The baseplate (21) and the plurality of exclusion reliefs (22) are defined at least in part by an elastic or flexible material in such a way that at least the baseplate (21) is elastically deformable at least during removal thereof from a multi-well cell-culture plate (10), the elastic or flexible material preferably being an elastomer.

Abstract: The invention relates to a microfluidic device which has at least one first culture chamber with cardiac muscular cells, at least one microfluidic channel, at least one pump (for example a micropump), and at least one detector, said detector being configured to detect an activity of the cardiac muscular cells contained in the culture chamber. The microfluidic device additionally contains at least one controller which is configured to control the at least one pump on the basis of the cardiac muscular cell activity detected by the at least one detector. The invention additionally relates to uses of the microfluidic device.

Abstract: Microfluidic devices and methods for perfusing a cell with perfusion fluid are provided herein, wherein the gravitational forces acting on the cell to keep the cell at or near a retainer or a retaining position exceed the hydrodynamic forces acting on the cell to move it toward an outlet. Also provided, are methods for assaying cell products within the microfluidic device.

Abstract: A method for producing a product related to the specified technology includes adjusting the concentration of cells in a culture vessel to a value of from 3×107 cells/ml to 3×108 cells/ml; in a case in which the average diameter of single cells in the culture vessel is designated as A, adjusting the number proportion of cells having a single cell diameter of 1.4×A or greater in the culture vessel to 5% or less, and adjusting the number proportion of cells having a single cell diameter in the range of A±A/7 to 50% or more.

Abstract: Methods, devices and kits for the physical separation of plankton into its component parts utilizing phototactic behavior are described. The methods utilize positive phototactic behavior and negative contrast orientation of the zooplankton for maximal in situ separation of phytoplankton and zooplankton for use in further studies and evaluation of separation efficiency. The devices provide effective conditions for use in the separation of plankton into component parts.

Abstract: The present disclosure provides instruments, modules and methods for improved detection of edited cells following nucleic acid-guided nuclease genome editing. The disclosure provides improved automated instruments that perform methods—including high throughput methods—for screening cells that have been subjected to editing and identifying cells that have been properly edited.

Abstract: The present disclosure provides instruments, modules and methods for improved detection of edited cells following nucleic acid-guided nuclease genome editing. The disclosure provides improved automated instruments that perform methods—including high throughput methods—for screening cells that have been subjected to editing and identifying cells that have been properly edited.

Abstract: An object of the present invention is to provide a method for preserving neural tissue for several hours to several weeks without freezing, a preservation solution therefor, a transport method for neural tissue in accordance with the method and using the preservation solution, and a composition for transplantation. The preservation method for neural tissue, comprising preserving neural tissue in a preservation solution having a potassium ion concentration of more than 0 mM and less than 115 mM at a preservation temperature of 8° C. to 30° C. The preservation solution having a potassium ion concentration of more than 0 mM and less than 115 mM, for preserving neural tissue derived from pluripotent stem cells at a preservation temperature of 8° C. to 30° C.

Abstract: Microorganisms and bioprocesses are provided that convert gaseous substrates, such as renewable H2 and waste CO2 producer gas, or syngas into high-protein biomass that may be used directly for human nutrition, or as a nutrient for plants, fungi, or other microorganisms, or as a source of soil carbon, nitrogen, and other mineral nutrients. Renewable H2 used in the processes described herein may be generated by electrolysis using solar or wind power. Producer gas used in the processes described herein may be derived from sources that include gasification of waste feedstock and/or biomass residue, waste gas from industrial processes, or natural gas, biogas, or landfill gas.

Abstract: Methods and compositions for long term continuous flow fermentation using a two vessel continuous culture fermentation apparatus are described.

Abstract: The invention provides for methods of viral inactivation using high temperature short time (HTST) treatment and adjustment of various parameters such that generation of precipitate and depositions of precipitate are reduced and/or minimized.

Abstract: The present invention relates to a cell culture medium using mammalian cells for producing a target material at high efficiency in the mammalian cells, a cell culturing method using same, and a method of producing the target material and, more particularly, to a cell culture medium including Zn ions at a concentration of 30?M or more in a culture, a salt thereof, or a chelate compound, a cell culturing method using same, and a method of producing a target material. According to the present invention, a cell culture medium for producing recombinant protein by using mammalian cells can be provided, which can achieve excellent effects in increasing antibody production, without showing any cell growth inhibiting effects.

Abstract: This document describes systems and methods for integrated mechanical loading of tissue. The system includes a three-dimensional tissue comprising organic material. The system includes a strip of bendable material. The strip includes a first region proximate to a first end of the strip coupled to the tissue. The strip includes a second region near a second end of the strip for coupled to the tissue, the second end being opposite the first end, wherein the tissue exerts a force on the strip to bend the strip, the force caused by contraction of the tissue, and wherein the strip exerts a stress on the tissue.

Abstract: By using a graft polymer comprising a dendritic polymer with a styrene skeleton and a hydrophilic polymer grafted to a terminal thereof, a temperature-responsive substrate for cell culture having a temperature-responsive surface for cell culture that allows cells to be cultured with high efficiency and which yet allows cultured cells to be exfoliated in a short period of time and with high efficiency by simply changing the temperature of the substrate surface can be prepared conveniently. If this temperature-responsive substrate for cell culture is used, cells obtained from a variety of tissues can be cultured with high efficiency. If this culture method is utilized, cultured cells can be exfoliated intact in a short amount of time with high efficiency. In addition, by using this graft polymer, a wide range of peptides and proteins can also be separated by simply changing the temperature of a chromatographic carrier.

Abstract: The present invention relates to the field of stem cell biology, in particular the linage specific differentiation of pluripotent or multipotent stem cells. Specifically described are methods to direct the lineage specific differentiation of hiPSC to sensitive neurons or neuronal fibers innervating the human skin, such as neural crest stem cells (NCPCs) and here called peripheral sensory neurons (PSNs) using novel culture conditions. It is also described a method for screening a biological agent in vitro. The PSNs obtained using the methods of the present invention are further contemplated for various uses including, but limited to, use in in vitro tests or disease modelling, such as drug discovery assays, cell therapy on a higher scale, detecting a range of skin irritants and other compounds of interest, for studying skin aging mechanism, and for producing a dermocosmetic product.

Abstract: The invention discloses the method of differentiating human induced Pluripotent Stem cells (iPS cells) to obtain pigmented cells which produce melanin. The protocol described is much more efficient than any other method used to obtain melanin in vitro.

Abstract: Provided are a universal T cell and preparation method thereof. The universal T cells comprise CAR-T and TCR-T cells, and are obtained by knocking out TCR and/or HLA and/or PD-1 proteins of T cells by a CRISPR/Cas9 genome editing technology, wherein the universal CAR-T continues to kill target cells in vivo and in vitro.

Abstract: Disclosed is a pro-inflammatory dendritic cell with improved ability to activate allo-geneic T-cells through the direct pathway of allorecognition. The dendritic cell is infected with an adenovirus. Further, the pro-inflammatory dendritic cell has been obtained by: —providing an immature dendritic cell; —infecting the dendritic cell with an adenovirus; and —maturating the immature dendritic cell into a pro-inflammatory dendritic cell by addition of the Toll-like receptor 3 (TLR3)-ligand poly-I:C, a TLR7/8-ligand, such as Resiquimod, and interferon gamma (IFN-?) to induce maturation of the immature dendritic cell.

Abstract: Healthy functional platelets are mass produced. A method for producing platelets, comprising: (1) a culture step of culturing megakaryocytes in a platelet producing medium in the presence of mechanical stress and platelet production promoting factors including MIF, NRDc, IGFBP2, TSP-1, PAI-1, and CCL5, and (2) a harvest step of harvesting the platelets obtained by the culture step; wherein the culture step comprises: (a) a step of promoting a release of the platelet production promoting factors from megakaryocytes by mechanical stress; and/or (b) a step of externally adding platelet production promoting factors including MIF, NRDc, and IGFBP2.

Abstract: The present invention provides a method for producing platelets that can improve at least one of the ability of megakaryocyte to produce platelets and the bioactivity of platelets produced even in high-density culture, for example. The method for producing platelets of the present invention includes a platelet producing step of producing platelets from megakaryocytes, wherein the platelet producing step is performed in the presence of at least one of glycine and cysteine.

Abstract: Provided is a method for producing platelets, in which damage to platelets is suppressed compared with a method in which platelets are separated using a filter from a megakaryocyte culture, and then the platelets are concentrated using a hollow fiber membrane and are further washed using the hollow fiber membrane, and purified platelets can be produced in a shorter period of time compared with the time that is taken to perform the above-described method so as to reduce damage to platelets. The method for producing purified platelets of the present invention includes a concentrating step of concentrating a megakaryocyte culture, and a centrifuging step of centrifuging platelets from an obtained concentrate.

Abstract: An isolated human NKT cell or a plurality of cells thereof, having reduced or no detectable expression of endogenous beta-2-microglobulin (B2M); endogenous MHC class II-associated invariant chain (Ii); or both. Methods to generate the cell or cells, and methods of treatment using the cell or cells are also provided.

Abstract: A method of creating a synthetic bone implant configured for implantation into a patient is provided. The method includes constructing a synthetic three dimensional composite support structure integrally formed as one piece, the synthetic three dimensional composite support structure including a nonbiodegradable material and having a porous construction with a plurality of passages, wherein the support structure is constructed to have a configuration corresponding to at least one of a bone and a portion of a bone to be replaced in the patient.

Abstract: The present invention is in the field of pluripotent stem cells, more particularly cardiomyocytes derived from pluripotent stem cells. The present invention provides a novel method for differentiating human pluripotent stem cells into a population of cardiomyocytes having an atrial phenotype, and use of said atrial cardiomyocytes for screening of drugs, AF disease model, and others. The method of the invention is particularly useful to generate cardiomyocytes having a more developed or mature atrialphenotype and/or to generate higher yield of cardiomyocytes having an atrialphenotype.

Abstract: The present invention relates to methods and compositions, including kits for reprogramming a source cell to a cardiomyocyte, the method comprising increasing the protein expression of one or more transcription factors, or variants thereof, in the source cell, wherein the source cell is reprogrammed to exhibit at least one characteristic of a cardiomyocyte.

Abstract: Provided are cytoplasts (enucleated cells), methods for making cytoplasts, compositions comprising cytoplasts, and methods for using cytoplasts.

Abstract: The present invention relates to the identification of a genomic integration site for heterologous polynucleotides in Chinese Hamster Ovary (CHO) cells resulting in high RNA and/or protein production. More specifically it relates to CHO cells comprising at least one heterologous polynucleotide stably integrated into the 5100A gene cluster of the CHO genome and to methods for the production of said CHO cells. Further, the invention relates to a method for the production of a protein of interest using said CHO cell and to the use of said CHO cell for producing a protein of interest at high yield. Integration within these specific target regions leads to reliable, stable and high yielding production of an RNA and/or protein of interest, encoded by the heterologous polynucleotide.

Abstract: Provided herein are, inter alia, compositions and methods for using genetically modified bioactive renal cell populations to provide regenerative effects to a native kidney for the treatment of chronic kidney disease. In certain embodiments, the aim is to effectively provide a “universal donor” immune-privileged renal cell population where gene editing is used to generate a modified allogeneic renal cell population to be administered to patients without immunosuppression.

Abstract: A cell culture medium for culturing organoid containing at lest two types of components selected from the group consisting of insulin-like growth factor 1 (IGH1), fibroblast growth factor 2 (FGF2) and epiregulin (EREG), and at least one type of component among the following components i (to III); i) Wnt agonist, ii) bone morphogenetic protein (BMP) inhibitor, and iii) transforming growth factor-? (TGIF-?) inhibitor.

Abstract: Methods of making vaccinia viruses for gene-directed prodrug therapy are disclosed and their use in the treatment of disease is provided. In particular, the anti-tumour effects of vaccinia viruses that are modified to express a prodrug activating enzyme are disclosed.

Abstract: The present invention provides compositions of CD180 targeting molecules coupled to heterologous antigens, and their use in treating and/or limiting disease.

Abstract: The present invention relates to a method for virus propagation. More closely the invention relates to a method for animal component free propagation and production of rotavirus (RV) using recombinant trypsin.

Abstract: Disclosed are ketoreductases and the use thereof. The disclosed ketoreductases are particularly useful for enzymatically catalyzing the reduction of ketones to chiral or non-chiral secondary alcohols and oxidation of chiral or non-chiral secondary alcohols to ketones.

Abstract: The present invention relates to a pharmaceutical, cosmetic or dermo-cosmetic composition that comprises DAO, for use in the prevention or treatment of diseases or pathological conditions associated with high levels of histamine in blood which involve an increase in pain, preferably fibromyalgia, characterised in that the application of the composition is topical.

Abstract: This disclosure provides vectors and strategies for increasing the efficiency of gene therapy in hepatocytes. The efficiency of the delivery of a corrected gene or wild type gene is improved through the use of delivery to hepatocytes via intrahepatic (parenchyma) administration or administration via the portal vein. In addition, the corrected gene or wild type gene is delivered using an isolated exogenous nucleic acid comprising a promoter that is specifically expressed in hepatocytes. These methods and isolated exogenous nucleic acids are useful to correct gene defects in the liver such as inherited diseases of the liver.

Abstract: Protein rupture under compressive forces can be regulated by cations. More specifically, pico-Newton forces can cause rupture of protein molecules, as shown in examples with calmodulin (CaM) and tau proteins, among others. However, rupture does not occur in the presence of various concentrations of cation(s), thus elucidating new targets for disease therapy and providing therapies for neurodegenerative diseases or other conditions involving protein misfolding, dysfunction, or aggregation.

Abstract: This invention pertains to mutant Cas12a nucleic acids and proteins for use in CRISPR/Cas2a endonuclease systems, and their methods of use. IN particular, the invention pertains to an isolated mutant Cas12a protein, wherein the isolated mutant Cas12a protein is active in a CRISPR/Cas12a endonuclease system. The invention also includes isolated nucleic acids encoding mutant Cas12a proteins, ribonucleoprotein complexes and CRISPR/Cas12a endonuclease systems having mutant Cast12a proteins.

Abstract: Transposase polypeptides and polynucleotides are provided, which have a high activity in mammalian cells. Methods for engineering cells, such as chimeric antigen T-cells, with the transposes are also provided.

Abstract: Described herein is at least one novel trypsin-like serine protease polypeptide and uses thereof. Further described herein are cleaning compositions containing at least one polypeptide described herein, wherein said composition can be used to clean fabrics and hard surfaces. Even further described herein is at least one cleaning composition selected from a laundry detergent, a dishwashing detergent (e.g., automatic and hand dish), and a personal care composition. Even still further, at least one polypeptide having improved soil removal and/or stability compared to at least one reference polypeptide is described herein.

Abstract: Fusion proteins containing a targeting sequence, exosporium protein, or exosporium protein fragment that targets the fusion protein to the exosporium of a recombinant Bacillus cereus family member are provided. The fusion proteins further comprise an enzyme having ACC deaminase activity, a phospholipase, a lipase, a xylanase, a xylosidase, a lactonase, a chitosanase, a protease, a glucanase, a phytase, an acid phosphatase, a pectinase, a mannanase, and/or an expansin protein. Also provided are recombinant Bacillus cereus family members that express the fusion proteins, exosporium fragments derived from the recombinant Bacillus cereus family members, and formulations containing the recombinant Bacillus cereus family members or exosporium fragments. Plant seeds treated with the recombinant Bacillus cereus family members, exosporium fragments, or formulations are also provided.

Abstract: Collection devices and kits for biological sample collection include a biologic sample collection device having a hydrophilic swab matrix that includes a modified polycaprolactone (PCL). Methods of production and use thereof are also described herein. The biologic sample collection devices, kits and methods described herein are used to collect a biologic sample (e.g., blood, buccal cells, etc.) and to enable extraction of nucleic acids (e.g., DNA) from that biologic sample so that the nucleic acids can be analyzed (e.g., sequencing and subsequent analyses of DNA).

Abstract: Methods and compositions for extracting nucleic acids such as microRNAs (miRNAs) from biological samples are provided. Aspects of the methods include contacting a biological sample with proteinase K followed by contact with ferric oxide particles under acidic conditions to induce binding between the ferric oxide particles and nucleic acids (e.g., miRNAs) of the sample. In some cases, the ferric oxide particles are provided as part of a dissolvable film, which releases the ferric oxide particles upon solvation. In some embodiments, after nucleic acids bind to the ferric oxide particles, the particles are magnetically separated from the sample and are contacted with an alkaline elution buffer to release the nucleic acids.

Abstract: Methods for processing polynucleotide-containing biological samples, and materials for capturing polynucleotide molecules such as RNA and/or DNA from such samples. The RNA and/or DNA is captured by polyamindoamine (PAMAM (Generation 0)) bound to a surface, such as the surface of magnetic particles. The methods and materials have high efficiency of binding RNA and of DNA, and of release, and thereby permit quantitative determinations.

Abstract: A method for nucleic acid isolation comprising: receiving a binding moiety solution within a process chamber; mixing the binding moiety solution with a biological sample, within the process chamber, in order to produce a moiety-sample mixture; incubating the moiety-sample mixture during a time window, thereby producing a solution comprising a set of moiety-bound nucleic acid particles and a waste volume; separating the set of moiety-bound nucleic acid particles from the waste volume; washing the set of moiety-bound nucleic acid particles; and releasing a nucleic acid sample from the set of moiety-bound nucleic acid particles. The method preferably utilizes a binding moiety comprising at least one of poly(allylamine) and polypropylenimine tetramine dendrimer, both of which reversibly bind and unbind to nucleic acids based upon environmental pH.

Abstract: Some aspects of this disclosure relate to systems, apparatuses, compositions (e.g., isolated nucleic acids and vectors), and methods for improving the stability and/or solubility of proteins evolved using phage-assisted continuous evolution (PACE). In some embodiments, vectors described herein comprise nucleic acids encoding selection systems (e.g., positive and/or negative selection systems) that link expression of genes required for production of infectious phage particles to a desirable physiochemical (e.g., stability or solubility) and/or desired function of an evolved protein.

Abstract: A method of preparing a conditionally active biologic protein by selecting a wild-type biologic protein, evolving the DNA which encodes the wild-type biologic protein using one or more evolutionary techniques to create mutant DNAs, expressing the mutant DNAs in a eukaryotic cell production host to obtain a mutant protein, subjecting the mutant protein and the wild-type protein to an assay under a normal physiological condition and to an assay under an aberrant condition, selecting a conditionally active mutant protein which exhibits at least one of: (a) a decrease in activity in the assay at the normal physiological condition compared to the wild-type protein, and (b) an increase in activity in the assay under the aberrant condition compared to the wild-type protein; and producing the conditionally active biologic protein in the same eukaryotic cell production host used in the expression step.

Abstract: The present invention relates to genetically modified bacteria and methods of optimizing genetically modified bacteria for the production of a metabolite.

Abstract: Disclosed is a method for obtaining a bifunctional complex comprising a molecule linked to a single stranded identifier oligonucleotide, wherein a nascent bifunctional complex comprising a chemical reaction site and a priming site for enzymatic addition of a tag is a) reacted at the chemical reaction site with one or more reactants, and b) reacted enzymatically at the priming site with one or more tag(s) identifying the reactant(s).

Abstract: The present invention relates to methods used in functional genomics that focus on gene function in a cell. The invention also relates to mutagenizing genes and generation of functional genetic mutants. The current invention also relates to methods for stimulus/drug-identification. In addition, the invention relates to the generation of cell lines showing a functional phenotype, most notably stimulus/drug-resistant cell lines. The current invention further relates to methods for identification of mutations conferring this phenotype. The current invention further relates to said methods and provides for rapid selection methods to identify targets and to identify stimulus/drug-target interactions and to identify mutations conferring stimulus/drug-resistance, more specifically said methods comprise the use of CRISPR/Cas systems, components thereof or the like.

Abstract: Provided are a PCR primer pair and an application thereof.